key: cord-0917754-bmsba67x
authors: Anai, Moriyasu; Akaike, Kimitaka; Iwagoe, Hajime; Akasaka, Takefumi; Higuchi, Takushi; Miyazaki, Aoi; Naito, Daiki; Tajima, Yuka; Takahashi, Hiroshi; Komatsu, Taiyo; Masunaga, Aiko; Kishi, Hiroto; Fujii, Kazuhiko; Fukuda, Koichiro; Tomita, Yusuke; Saeki, Sho; Ichiyasu, Hidenori; Sakagami, Takuro
title: Decrease in Hemoglobin Level Predicts Increased Risk for Severe Respiratory Failure in COVID-19 Patients with Pneumonia
date: 2020-11-23
journal: Respir Investig
DOI: 10.1016/j.resinv.2020.10.009
sha: e1b6ec7482ea8673a14970881f12d2cb79583a3a
doc_id: 917754
cord_uid: bmsba67x

BACKGROUND: In December 2019, the coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in Wuhan, China, and has since spread throughout the world. This study aimed to investigate the association between the change in laboratory markers during the three days after pneumonia diagnosis and severe respiratory failure in COVID-19 patients. METHODS: Data of 23 COVID-19 patients with pneumonia, admitted to the Kumamoto City Hospital between February and April 2020 were retrospectively analyzed. RESULTS: Among the 23 patients, eight patients received mechanical ventilation (MV) (MV group), and the remaining 15 comprised the non-MV group. The levels of hemoglobin (Hb) and albumin (Alb) decreased in the MV group during the three days after pneumonia diagnosis more than in the non-MV group (median Hb: -1.40 vs. -0.10 g/dL, P = 0.015; median Alb: -0.85 vs. -0.30 g/dL, P = 0.020). Univariate logistic regression analysis showed that the decrease in Hb was associated with receiving MV care (odds ratio: 0.313, 95% confidence interval: 0.100–0.976, P = 0.045). Receiver operating characteristic curve analyses showed that the optimal cut-off value for the decrease in Hb level was -1.25 g/dL, with sensitivity and specificity values of 0.867 and 0.750, respectively. CONCLUSIONS: The decrease in Hb level during the short period after pneumonia diagnosis might be a predictor of worsening pneumonia in COVID-19 patients.

Background: In December 2019, the coronavirus disease , caused by the 30 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), emerged in Wuhan, 31

China, and has since spread throughout the world. This study aimed to investigate the 32 association between the change in laboratory markers during the three days after 33 pneumonia diagnosis and severe respiratory failure in COVID-19 patients. Coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses 67 [1] . This coronavirus disease 2019 (COVID-19) was declared a public health emergency 68 of international concern by the World Health Organization [2] . Studies 

In severe respiratory failure cases that needed more than 5 L/min oxygen flow through 105 a face mask, intubation and MV was considered. After intubation, the mechanical 106 ventilator was set to positive end-expiratory pressure of more than 10 cmH 2 O. Fisher's exact test and Mann-Whitney U test were used to compare the clinical values 116 between the two patient groups. Univariate logistic regression analysis was performed 117 to evaluate the association between the laboratory variables and MV treatment. In 118 addition, a receiver operating characteristic (ROC) curve analysis was performed to 119 determine the optimal cut-off value for predicting the introduction of MV care. All 120 analyses were two-tailed, and differences with a P-value < 0.05 were considered 121 statistically significant. Statistical analysis was performed using the SPSS software 122 

The median follow-up was 33 days (range: 16-102 days). In the MV group, the median 147 days from the onset of illness and pneumonia diagnosis to the initiation of MV were 148 nine days (range 5-26 days; Figure 1A ) and six days (range 0-20 days; Figure 1B The most commonly reported reason for mortality or the development of a severe 207 disease that requires MV care is the cytokine storm syndrome caused by SARS-CoV-2 208

[4]. Particularly, elevated IL-6 level was reported to be part of a larger cytokine storm, 209 and associated with poor prognosis [15] . Another study found that IL-6 level in 210 COVID-19 patients with oxygen saturation (SpO 2 ) < 90% was significantly higher than 211 in those with SpO 2 > 90% (median IL-6, 51.69 vs. 6.69 pg/mL, P < 0.001) [6]. Thus, 212 IL-6 level is thought to play an important role in the cytokine network associated with 213 severe respiratory failure, including ARDS, in COVID-19 patients. these patients is thought to be due to elevated IL-6. One possible reason is the fact that 220

the patients in the current study had no evidence of hemorrhagic diathesis. Additionally, 221

previous studies have reported that IL-6 induces the liver to synthesize acute phase 222 proteins, including CRP [17]. In the current study, the CRP level in the MV group was 223 significantly higher than in the non-MV group, which indicates that IL-6 level may have 224 exhibited similar tendencies. Thus, the decrease in Hb level might be associated with 225 elevated IL-6 level, and as such, can be useful for predicting poor prognosis ( Figure S1 , 226

In the current study, we evaluated the rate of change in laboratory factors over the J o u r n a l P r e -p r o o f 

The origin, 265 transmission and clinical therapies on coronavirus disease 2019 (COVID-19) 266 outbreak -an update on the status

WHO Declares COVID-19 a Pandemic

Clinical 270 Characteristics of Coronavirus Disease 2019 in China

Clinical features of patients 273 infected with 2019 novel coronavirus in Wuhan

Presenting Characteristics, Comorbidities, and Outcomes Among 5700

Patients Hospitalized With COVID-19 in the New York City Area

Prognostic value of interleukin-6

C-reactive protein, and procalcitonin in patients with COVID-19

Chest CT manifestations of new 283 coronavirus disease 2019 (COVID-19): a pictorial review

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Favipiravir, an antiviral for COVID-19?

All authors are required to disclose any COI within 3 calendar years preceding the current year, prior to the submission of any manuscript in the subject matter of which any company, entity, or organization has an interest.

No If Yes: List the name(s) of authors and commercial entity(ies) and use as much space as necessary